An 11-year-old boy with severe aplastic anemia underwent unrelated BMT following TBI, antithymocyte globulin and CY. On day +23, CMV antigenemia was detected which resolved with ganciclovir. Eight days after discontinuing ganciclovir, he complained of impaired visual acuity. Ophthalmologic findings and a positive PCR study using anterior chamber fluid from the right eye confirmed the presumptive diagnosis of CMV retinitis, although CMV antigenemia and PCR studies using PBMC were then negative. He was successfully re-treated with ganciclovir. CMV retinitis should be considered even when CMV antigenemia is not present or PCR using PBMC is negative.
to the protocol of the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology 5 because no HLA-matched related BMT donor was available. Hematological remission was achieved by the treatment but he required continued CsA, danazol and G-CSF to maintain his remission. Six months after the initial diagnosis, a BMT from an unrelated donor was performed. The conditioning regimen consisted of TBI 250 cGy twice daily for 2 consecutive days (total 1000 cGy), ATG 2.5 mg/kg once daily i.v. for 4 consecutive days (total four doses) and CY 60 mg/kg once daily i.v. for 2 consecutive days (total dose 120 mg/kg). GVHD prophylaxis was with CsA and shortterm MTX. Serological examination for CMV revealed that the recipient was positive but the donor was negative. Hightiter immunoglobulin against CMV 250 mg/kg was given every week from day Ϫ7.
Engraftment was obtained 15 days after transplantation. Routine screening for CMV infection was performed and CMV antigenemia was first detected on day +23 at a level of eight positive cells per 300 000 leukocytes. CMV-PCR using PBMC was positive, but CMV was not isolated from urine. CMV disease, defined as presence of esophagitis, enteritis, hepatitis or pneumonia was not observed. We administered GCV 5 mg/kg once daily i.v. until day +131 when CMV antigenemia was undetectable. High-titer immunoglobulins were administered until day +134. The peak level of antigenemia observed was 307 positive cells on day +64. No aGVHD occurred.
On day +139, 8 days after cessation of GCV, he complained of visual 'floaters' with decreasing visual acuity. Ophthalmologic examination on day +140 disclosed papilledema, confluent patches of fluffy white-yellow intraretinal infiltrates and streaky hemorrhages in both eyes. Although CMV antigenemia, CMV PCR and urine exam were all negative, CMV DNA was detectable by PCR in the anterior chamber fluid of the right eye, thereby confirming the diagnosis of CMV. He was receiving CsA in a tapering dose at the time.
He was treated with i.v. GCV 5 mg/kg twice daily for 2 weeks, once daily for 2 weeks and then 5 days a week for over 4 months. He also received high-titer anti-CMV immunoglobulins, 400 mg/kg i.v. every other day for four doses, 250 mg/kg i.v. twice a week for 3 weeks and then once a week for another 7 weeks. Two weeks after starting treatment, regression of his retinitis was observed. As complete regression of both infiltrates and hemorrhages was observed 3 months after treatment, an operation to prevent retinal detachment in the right eye was performed. CMV-PCR using the anterior chamber fluid of the right eye was performed again without detection of the CMV genome. Over the next 2 months complete regression of all formerly active lesions was observed and visual acuity returned to normal.
Discussion
CMV disease is a major complication in patients with AIDS or after BMT. The main clinical manifestations of CMV disease after BMT are esophagitis, enteritis and interstitial pneumonia, 1 although CMV is known to infect many organs, including the liver, lung, digestive tract, brain, bone marrow and eye. 6 CMV retinitis affects as many as 40% of patients with AIDS. 2 However, a retrospective study suggested that the incidence of CMV retinitis in childhood BMT recipients is extremely low. 3 The reason for this low incidence of CMV retinitis in BMT recipients is unknown.
Many patients with CMV infection are treated successfully with ganciclovir, foscarnet or high-titer anti-CMV gamma globulin. Active CMV infection can still cause significant morbidity and mortality in BMT recipients.
1 CMV antigenemia-guided pre-emptive ganciclovir therapy is reported to prevent CMV disease in allogeneic BMT recipients. 4 In our patient, the initial asymptomatic CMV infection was treated by pre-emptive ganciclovir therapy. Nevertheless, CMV retinitis occurred after cessation of GCV therapy in spite of a lack of CMV antigenemia, negative CMV-PCR studies using PBMC and negative urine viral studies.
CMV cannot be eliminated by GCV treatment and CMV infections may return within as little as 1 week following GCV treatment in patients with AIDS. 2 Cytotoxic T lymphocyte (CTL) function is most critical for protection from severe CMV disease and mortality in the setting of both BMT and AIDS. 1 This patient received ATG twice during the course of his treatment. ATG administration might be implicated in the development of CMV retinitis because it causes severe depression of cellular immunity. However, some sites, including the eye, have been defined as regions of the body where the immune system appears not to function. In mice, Fas ligand can be detected in the eye and Fas expressing infiltrating cells such as activated lymphocytes are promptly induced to undergo apoptosis by FasFas ligand interaction. 7 This experiment suggests cellular immunology might not be crucial in CMV retinitis.
Viremia caused by glycoprotein B group 2 CMV strains was reported to be associated with a higher risk of CMV retinitis than viremia due to other CMV glycoprotein B groups in AIDS. 8 Consequently, we examined the glycoprotein B group of the CMV causing the viremia in our patient which proved to be not 2 but 3 (data not shown). This is the group commonly found in Japan.
We administered GCV at a maintenance dose from the time antigenemia was first detected, because the CMV infection was asymptomatic and only small numbers of CMV positive cells were detected. If asymptomatic CMV retinitis was present from the beginning, the dosage used might be insufficient to eliminate CMV in the eye though it was sufficient to eliminate antigenemia.
In conclusion, it is prudent to be aware of the risk of CMV retinitis in such patients even when screening tests are negative and apparently adequate therapy has been given.
